title: Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.
authors.affiliation: Oregon Medical Research Center, Suite G, 9495 S. Locust Street, Portland, OR 97223, OR, U.S.A.
authors.forename: A
authors.identifier: 0000-0002-2633-985X
authors.initials: A
authors.lastname: Blauvelt
authors.affiliation: Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.
authors.forename: C E M
authors.initials: CEM
authors.lastname: Griffiths
authors.affiliation: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY, U.S.A.
authors.forename: M
authors.initials: M
authors.lastname: Lebwohl
authors.affiliation: Psoriasis Center at the Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Kiel, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Mrowietz
authors.affiliation: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
authors.forename: L
authors.identifier: 0000-0001-6083-0952
authors.initials: L
authors.lastname: Puig
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: S
authors.initials: S
authors.lastname: Ball
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: E
authors.initials: E
authors.lastname: Edson-Heredia
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: M
authors.initials: M
authors.lastname: Warner
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: B
authors.initials: B
authors.lastname: Zhu
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: C-Y
authors.initials: CY
authors.lastname: Lin
authors.affiliation: Eli Lilly Belgium, Brussels, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Nikaï
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: D
authors.initials: D
authors.lastname: Dey
authors.affiliation: Eli Lilly and Co., Indianapolis, IN, U.S.A.
authors.forename: L
authors.initials: L
authors.lastname: Mallbris
authors.affiliation: Dermatologikum Hamburg, Hamburg, Germany.
authors.forename: K
authors.identifier: 0000-0001-5248-4332
authors.initials: K
authors.lastname: Reich
mesh_terms: D000704:Analysis of Variance; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068800:Etanercept / Q000008:administration & dosage*; D006801:Humans; D000071066:Patient Reported Outcome Measures; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; C549079:ixekizumab; D000068800:Etanercept